Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $456,790.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the sale, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Eben Tessari also recently made the following trade(s):

• On Monday, September 23rd, Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $24.99, for a total value of $437,325.00.
• On Tuesday, August 27th, Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $26.91, for a total value of $470,925.00.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA opened at $26.26 on Friday. The firm has a market capitalization of $1.86 billion, a P/E ratio of 238.73 and a beta of 0.33. The stock has a 50-day simple moving average of $25.58 and a two-hundred day simple moving average of $21.96. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $14.12 and a fifty-two week high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The company had revenue of $108.30 million during the quarter, compared to analysts’ expectations of $90.60 million. During the same period last year, the business earned ($0.02) earnings per share. Kiniksa Pharmaceuticals’s quarterly revenue was up 51.5% on a year-over-year basis. As a group, analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on KNSA shares. Wedbush increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $33.60.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Hhlr Advisors LTD. acquired a new position in shares of Kiniksa Pharmaceuticals in the first quarter worth about $61,868,000. Vanguard Group Inc. raised its holdings in Kiniksa Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock worth $58,833,000 after purchasing an additional 16,595 shares during the period. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares during the period. Finally, Millennium Management LLC increased its position in shares of Kiniksa Pharmaceuticals by 159.8% in the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock valued at $11,612,000 after buying an additional 382,539 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.